What is Seres Therapeutics's latest dividend and current dividend yield?

What is Seres Therapeutics's gross profit margin?

What is the market's earnings forecast for Seres Therapeutics next quarter?

Did Seres Therapeutics beat or miss consensus estimates last quarter?

What guidance did Seres Therapeutics's management provide for the next earnings period?

What is the revenue and EPS growth rate for Seres Therapeutics year over year?

What were the key takeaways from Seres Therapeutics’s earnings call?

What were the key takeaways from Seres Therapeutics's earnings call?

- **SER-155 Clinical Momentum**: Phase two alloHSCT trial design aligned with FDA, with interim analysis results anticipated within 12 months. Study could validate 77% risk reduction in bacterial BSIs, positioning for potential regulatory approval pathway.
- **Expanded Access Potential**: CARB-X funding for oral liquid SER-155 formulation targets critically ill patients (e.g., ICU, pediatric) unable to swallow capsules, broadening therapeutic reach and addressing unmet need in antimicrobial resistance.
- **Strategic Flexibility**: Management pursuing non-dilutive funding and partnerships to advance phase two without equity dilution, maintaining financial discipline amid capital raising efforts.
- **Market Expansion**: IREC study could unlock $30B+ ICI therapy market, addressing side effects that force treatment interruptions and hospitalizations.
- **Financial Resilience**: 25% workforce reduction extends cash runway to Q2 2026, supporting dual-track development of SER-155 and pipeline candidates.


**【CEO/CFO Opening Remarks】**
- **SER-155 Phase 2 Study Progress**: Received FDA alignment on protocol for phase two alloHSCT trial, with interim analysis results expected within 12 months of study initiation. The study aims to demonstrate a 77% relative risk reduction in bacterial BSIs observed in phase one B.
- **Cost Reduction Measures**: Implemented 25% workforce reduction, extending cash runway to Q2 2026. Focus remains on advancing SER-155 and core pipeline.
- **Financial Highlights**: Q3 2025 net income of $8.2M (vs. $51M loss in Q3 2024), driven by $27.2M gain from VAST sale. R&D expenses down 24% YoY to $12.6M, reflecting completion of phase one B study.

**【Chief Scientific Officer Commentary】**
- **CARB-X Award**: Secured $3.6M to develop oral liquid SER-155 formulation for expanded patient access, including ICU and pediatric populations. This funding underscores global recognition of SER-155’s potential to address antimicrobial resistance.
- **IREC Study Update**: Memorial Sloan Kettering trial enrolling patients with immune checkpoint inhibitor-related enterocolitis (IREC), targeting a condition affecting up to 50% of ICI therapy recipients. Early 2026 data expected on safety, pharmacokinetics, and diarrhea symptom response.

**【Q&A Highlights】**
- **Capital Needs & Partnership Strategy**: Management emphasizes phase two study is “funding-dependent,” with focus on securing non-dilutive funding and strategic partnerships to accelerate development without dilution.
- **Commercial Opportunity Validation**: IREC study could expand SER-155’s addressable market beyond alloHSCT, with potential to mitigate ICI therapy side effects and improve patient outcomes.
- **Cash Runway Confidence**: Current $47.6M cash balance supports operations through Q2 2026, with prioritization of SER-155 development and clinical trial preparation activities.


Seres Therapeutics, Inc. (MCRB) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

MCRB

MCRB fundamentals

You can ask Aime